{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:25:56Z","timestamp":1760747156098,"version":"build-2065373602"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00720-7","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:44:13Z","timestamp":1758638653000},"page":"679-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the Biosimilars from Bench to Bedside in Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6377-2024","authenticated-orcid":false,"given":"Elaine M.","family":"Yung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Fridley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1708-4059","authenticated-orcid":false,"given":"Tracy","family":"Matheny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"720_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108447","author":"O Aragon Cuevas","year":"2020","unstructured":"Aragon Cuevas O, Hedrich CM. Biosimilars in pediatric rheumatology and their introduction into routine care. Clin Immunol. 2020. https:\/\/doi.org\/10.1016\/j.clim.2020.108447.","journal-title":"Clin Immunol"},{"key":"720_CR2","first-page":"11","volume":"450","author":"SP Starr","year":"2016","unstructured":"Starr SP. Immunology update: biologics. FP Essent. 2016;450:11\u201321.","journal-title":"FP Essent."},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s40267-021-00844-z","volume":"37","author":"M Olave","year":"2021","unstructured":"Olave M, Lavery C, Leonard CE, et al. Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs Ther Perspect. 2021;37:338\u201346.","journal-title":"Drugs Ther Perspect"},{"key":"720_CR4","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0117","author":"V Abitbol","year":"2023","unstructured":"Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023. https:\/\/doi.org\/10.57264\/cer-2023-0117.","journal-title":"J Comp Eff Res"},{"key":"720_CR5","unstructured":"Title 42\u2014The Public Health and Welfare Act. Office of the Law Revision Counsel of the U.S. House of Representatives. 2023. https:\/\/uscode.house.gov\/view.xhtml?req=(title:42%20section:262%20edition:prelim)%5B1. Accessed 1 Jul 2025."},{"key":"720_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12656","author":"F de Mora","year":"2015","unstructured":"de Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015. https:\/\/doi.org\/10.1111\/bcp.12656.","journal-title":"Br J Clin Pharmacol"},{"key":"720_CR7","unstructured":"Ong M, Schiff G, Natter M. Incidence, contributing factors, and impact of diagnostic delay in juvenile idiopathic arthritis: analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. 2020. https:\/\/acrabstracts.org\/abstract\/incidence-contributing-factors-and-impact-of-diagnostic-delay-in-juvenile-idiopathic-arthritis-analysis-of-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry\/. Accessed 20 Jan 2025."},{"key":"720_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24853","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2022. https:\/\/doi.org\/10.1002\/acr.24853.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"720_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23870","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019. https:\/\/doi.org\/10.1002\/acr.23870.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"720_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41879","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, et al. Definition and validation of the American college of rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.41879.","journal-title":"Arthritis Rheumatol"},{"key":"720_CR11","unstructured":"Biehn B, Nelson D. U.S. biosimilar landscape. Cencora. 2025. https:\/\/www.cencora.com\/-\/media\/assets\/corporate\/global\/resource-pages\/cencora-biosimilars-usmarketlandscape-apr25.pdf. Accessed 25 Jan 2025."},{"key":"720_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0310-z","author":"S Stergiopoulos","year":"2015","unstructured":"Stergiopoulos S, Getz K. Evaluating AE reporting of two off-patent biologics to inform future biosimilar naming and reporting practices. Drug Saf. 2015. https:\/\/doi.org\/10.1007\/s40264-015-0310-z.","journal-title":"Drug Saf"},{"key":"720_CR13","unstructured":"Nonproprietary naming of biological products guidance for industry. FDA. 2017. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonproprietary-naming-biological-products-guidance-industry. Accessed 25 Jan 2025."},{"key":"720_CR14","unstructured":"Joszt L. The wait is over: 8 adalimumab biosimilars launching in the US in July. AMJC. 2023. https:\/\/www.ajmc.com\/view\/the-wait-is-over-8-adalimumab-biosimilars-launching-in-the-us-in-july. Accessed 29 Jun 2025."},{"key":"720_CR15","unstructured":"Purple book: database of licensed biological products. U.S. Food and Drug Administration. 2025. https:\/\/purplebook.fda.gov. Accessed 1 Apr 2025."},{"key":"720_CR16","unstructured":"Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. U.S. Food and Drug Administration. 2020. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or?trk=public_post_comment-text. Accessed 25 Mar 2025."},{"key":"720_CR17","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24104","author":"SD Sullivan","year":"2024","unstructured":"Sullivan SD, Humphreys SZ, Fox D, et al. Stakeholder perspectives on the sustainability of the United States biosimilars market. J Manag Care Spec Pharm. 2024. https:\/\/doi.org\/10.18553\/jmcp.2024.24104.","journal-title":"J Manag Care Spec Pharm"},{"key":"720_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00087-0","author":"L Kearsley-Fleet","year":"2024","unstructured":"Kearsley-Fleet L, Baildam E, Beresford MW, et al. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study. Lancet Rheumatol. 2024. https:\/\/doi.org\/10.1016\/S2665-9913(24)00087-0.","journal-title":"Lancet Rheumatol"},{"key":"720_CR19","unstructured":"Commissioning framework for biological medicines. NHS. 2017. https:\/\/www.england.nhs.uk\/publication\/commissioning-framework-for-biological-medicines\/. Accessed 12 Dec 2024."},{"key":"720_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1166","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.1166.","journal-title":"JAMA"},{"key":"720_CR21","unstructured":"Fontanillo M, K\u00f6rs B, Monnard A. The biosimilars market is poised to grow over the next decade. McKinsey & Company. 2022. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/three-imperatives-for-r-and-d-in-biosimilars#\/. Accessed 20 Jan 2025."},{"key":"720_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030321","author":"MA Cordeiro","year":"2024","unstructured":"Cordeiro MA, Vitorino C, Sinogas C, Sousa JJ. A regulatory perspective on biosimilar medicines. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16030321.","journal-title":"Pharmaceutics"},{"key":"720_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115543","author":"S Mill\u00e1n-Mart\u00edn","year":"2023","unstructured":"Mill\u00e1n-Mart\u00edn S, Jakes C, Carillo S, Bones J. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars. J Pharm Biomed Anal. 2023. https:\/\/doi.org\/10.1016\/j.jpba.2023.115543.","journal-title":"J Pharm Biomed Anal"},{"key":"720_CR24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051215-031022","author":"LA Christl","year":"2017","unstructured":"Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017. https:\/\/doi.org\/10.1146\/annurev-med-051215-031022.","journal-title":"Annu Rev Med"},{"key":"720_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.909","author":"MK Dougherty","year":"2018","unstructured":"Dougherty MK, Zineh I, Christl L. Perspectives on the current state of the biosimilar regulatory pathway in the United States. Clin Pharmacol Ther. 2018. https:\/\/doi.org\/10.1002\/cpt.909.","journal-title":"Clin Pharmacol Ther"},{"key":"720_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003757","author":"S White","year":"2023","unstructured":"White S, Morrow R, Pan I, de Zoeten EF. Riding the wave of adalimumab biosimilars: considerations for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr. 2023. https:\/\/doi.org\/10.1097\/MPG.0000000000003757.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"720_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00402-0","author":"HC Ebbers","year":"2020","unstructured":"Ebbers HC, Fehrmann B, Ottosen M, et al. Batch-to-batch consistency of SB4 and SB2, etanercept and infliximab biosimilars. BioDrugs. 2020. https:\/\/doi.org\/10.1007\/s40259-019-00402-0.","journal-title":"BioDrugs"},{"key":"720_CR28","unstructured":"Considerations in demonstrating interchangeability with a reference product: update. FDA. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update. Accessed 25 Mar 2025."},{"key":"720_CR29","unstructured":"Biologics Price Competition and Innovation Act of 2009. FDA. 2016. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/implementation-biologics-price-competition-and-innovation-act-2009. Accessed 1 July 2025."},{"key":"720_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638444","author":"X Lu","year":"2021","unstructured":"Lu X, Hu R, Peng L, Liu M, Sun Z. Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.638444.","journal-title":"Front Immunol"},{"key":"720_CR31","unstructured":"Care CoR. Position statement: biosimilars. American College of Rheumatology. 2024. https:\/\/rheumatology.org\/biosimilars. Accessed 1 Mar 2025."},{"key":"720_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","author":"K Feng","year":"2024","unstructured":"Feng K, Russo M, Maini L, Kesselheim AS, Rome BN. Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum. 2024. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.5429.","journal-title":"JAMA Health Forum"},{"key":"720_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0338","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0338.","journal-title":"JAMA Intern Med"},{"key":"720_CR34","unstructured":"Jeremias S. FDA approves first subcutaneous infliximab product. AJMC. 2023. https:\/\/www.centerforbiosimilars.com\/view\/fda-approves-first-subcutaneous-infliximab. Accessed 1 Jul 2025."},{"issue":"12","key":"720_CR35","first-page":"29","volume":"18","author":"KAR Ferguson","year":"2024","unstructured":"Ferguson KAR. Caught in the crosshairs. Rheumatologist. 2024;18(12):29.","journal-title":"Rheumatologist"},{"key":"720_CR36","unstructured":"FAILURE TO LAUNCH\u2014Barriers to biosimilar market adoption. AAM. 2019. https:\/\/www.biosimilarscouncil.org\/wp-content\/uploads\/2019\/09\/AAM-Biosimilars-Council-Failure-to-Launch-2-web.pdf. Accessed 1 Jul 2025."},{"key":"720_CR37","unstructured":"Slavin E. CVS Health launches Cordavis. CVS Health. 2023. https:\/\/www.cvshealth.com\/news\/pbm\/cvs-health-launches-cordavis.html. Accessed 25 Mar 2025."},{"key":"720_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00526-w","author":"FG Demirkan","year":"2022","unstructured":"Demirkan FG, S\u00f6nmez HE, Lamot L, Akg\u00fcn \u00d6, S\u00f6zeri B, Ayaz NA. Embracing change: an international survey study on the beliefs and attitudes of pediatric rheumatologists towards biosimilars. BioDrugs. 2022. https:\/\/doi.org\/10.1007\/s40259-022-00526-w.","journal-title":"BioDrugs"},{"key":"720_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16275","author":"WF Gellad","year":"2019","unstructured":"Gellad WF, Good CB. Adalimumab and the challenges for biosimilars. JAMA. 2019. https:\/\/doi.org\/10.1001\/jama.2019.16275.","journal-title":"JAMA"},{"key":"720_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.115","author":"L Colloca","year":"2012","unstructured":"Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012. https:\/\/doi.org\/10.1001\/jama.2012.115.","journal-title":"JAMA"},{"key":"720_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1025","author":"R Brouwer","year":"2022","unstructured":"Brouwer R, Ten Klooster PM, Masselink JB, Vonkeman HE. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: an observational study in rheumatoid arthritis patients. Pharmacol Res Perspect. 2022. https:\/\/doi.org\/10.1002\/prp2.1025.","journal-title":"Pharmacol Res Perspect"},{"key":"720_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210459","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459.","journal-title":"Ann Rheum Dis"},{"key":"720_CR43","unstructured":"Several new biosimilars for Humira available now. Spondylitis Association of America. 2023. https:\/\/spondylitis.org\/research-new\/several-new-biosimilars-for-humira-available-now\/. Accessed 20 Mar 2025."},{"key":"720_CR44","unstructured":"SIMLANDI\u00ae (adalimumab-ryvk) autoinjector. Arthritis Foundation. https:\/\/www.arthritis.org\/partnership\/ease-of-use-products\/simlandi-button-free-autoinjector. Accessed 10 Mar 2025."},{"key":"720_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02818-9","author":"JR Allegretti","year":"2024","unstructured":"Allegretti JR, Brady JH, Wicker A, Latymer M, Wells A. Relevance of adalimumab product attributes to patient experience in the biosimilar era: a narrative review. Adv Ther. 2024. https:\/\/doi.org\/10.1007\/s12325-024-02818-9.","journal-title":"Adv Ther"},{"key":"720_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2024.08.003","author":"MF Gicchino","year":"2025","unstructured":"Gicchino MF, Capasso G, Amodio A, Miraglia Del Giudice E, Olivieri AN, Di Sessa A. Biosimilars versus originators in children with juvenile idiopathic arthritis: a real-world experience. J Pediatr Health Care. 2025. https:\/\/doi.org\/10.1016\/j.pedhc.2024.08.003.","journal-title":"J Pediatr Health Care"},{"key":"720_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab572","author":"I Maccora","year":"2022","unstructured":"Maccora I, Lombardi N, Crescioli G, et al. Obsidian - Real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis. Rheumatology (Oxford). 2022. https:\/\/doi.org\/10.1093\/rheumatology\/keab572.","journal-title":"Rheumatology (Oxford)"},{"key":"720_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11325","author":"F Thiele","year":"2021","unstructured":"Thiele F, Klein A, Hospach A, et al. Efficacy and safety of etanercept biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study. ACR Open Rheumatol. 2021. https:\/\/doi.org\/10.1002\/acr2.11325.","journal-title":"ACR Open Rheumatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00720-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:09Z","timestamp":1760714949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00720-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00720-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflicts of interest relevant to this article to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable, article did not collect data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All four authors, Elaine M. Yung, Amanda Fridley, Tracy Matheny and Hermine I. Brunner have contributed significantly to writing the manuscript. All authors have read and approve the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}